58 Spam-Free Article(s) Found
Sort:
Relevance
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Monday’s Close
TEVA Teva Pharmaceutical Industries Limited $23.43 $23.86B N/A
Article Searches
State of Virginia sues Teva Pharmaceuticals over opioids http://www.startribune.com/state-of-virginia-sues-teva-pharmaceuticals-over-opioids/564164142/ Oct 31, 2019 - Virginia's attorney general filed a new lawsuit Thursday over the opioid crisis, even as the top government lawyers in some states are pushing to settle claims over powerful prescription painkillers.
Teva Pharmaceutical Industries Ltd. (TEVA) Dips More Than Broader Markets: What You Should Know http://www.zacks.com/stock/news/597013/teva-pharmaceutical-industries-ltd-teva-dips-more-than-broader-markets-what-you-should-know?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6-597013 Oct 31, 2019 - Teva Pharmaceutical Industries Ltd. (TEVA) closed at $8.15 in the latest trading session, marking a -0.49% move from the prior day.
What's in the Cards for Teva (TEVA) This Earnings Season? http://www.zacks.com/stock/news/602734/whats-in-the-cards-for-teva-teva-this-earnings-season?cid=CS-ZC-FT-analyst_blog|earnings_preview-602734 Nov 04, 2019 - Pricing erosion in U.S. generics market and rapid erosion in sales of Copaxone are likely to have hurt Teva's (TEVA) Q3 sales
Mylan's (MYL) Q3 Earnings Beat Estimates, Revenues Miss http://www.zacks.com/stock/news/604734/mylans-myl-q3-earnings-beat-estimates-revenues-miss?cid=CS-ZC-FT-analyst_blog|earnings_article-604734 Nov 05, 2019 - Mylan's (MYL) earnings beat estimates but sales miss the same in the third quarter of 2019. The company updates guidance for 2019.
Teva (TEVA) Q3 Earnings Miss, Sales Top Estimates, Stock Up http://www.zacks.com/stock/news/608243/teva-teva-q3-earnings-miss-sales-top-estimates-stock-up?cid=CS-ZC-FT-tale_of_the_tape|earnings_report-608243 Nov 07, 2019 - Teva Pharmaceutical (TEVA) misses earnings estimate but beats the same for sales. Shares rise in pre-market trading.
Here's Why Teva Pharmaceuticals Gained 18.5% in October https://www.fool.com/investing/2019/11/07/heres-why-teva-pharmaceuticals-gained-185-in-octob.aspx?source=iedfolrf0000001 Nov 07, 2019 - Investors grew optimistic that the company's legal and financial risks from the ongoing opioid epidemic may be coming to an end.
Teva Pharmaceutical Industries Limited (TEVA) CEO Kare Schultz on Q3 2019 Results - Earnings Call Transcript https://seekingalpha.com/article/4303822-teva-pharmaceutical-industries-limited-teva-ceo-kare-schultz-q3-2019-results-earnings-call?source=feed_tag_israel Nov 07, 2019 - Teva Pharmaceutical Industries Limited (NYSE:TEVA) Q3 2019 Results Conference Call November 07, 2019 08:00 AM ET Company Participants Kevin Mannix - Senior Vice President of Investor Relations Kare Sc
5 Low Price-to-Book Stocks to Buy in November http://www.zacks.com/stock/news/609952/5-low-price-to-book-stocks-to-buy-in-november?cid=CS-ZC-FT-analyst_blog|rw-609952 Nov 08, 2019 - P/B ratio is emerging as a convenient tool for identifying low-priced stocks that have high growth prospects.
Teva launches $1.5B debt offering https://seekingalpha.com/news/3517269-teva-launches-1_5b-debt-offering?source=feed_news_all Nov 08, 2019 - Aimed at rolling over three series of outstanding debt due in 2021, Teva Pharmaceutical Industries (TEVA +4.5%) launches a $1.5B private offering Euro-denominated Senior Notes.Pricing and terms have y
Teva (TEVA) Q3 Earnings Miss, Stock Up on Guidance Increase http://www.zacks.com/stock/news/610241/teva-teva-q3-earnings-miss-stock-up-on-guidance-increase?cid=CS-ZC-FT-analyst_blog|earnings_article-610241 Nov 08, 2019 - Teva Pharmaceutical (TEVA) misses earnings estimate but beats the same for sales. The company increases the lower end of its 2019 sales and earnings guidance. Shares rise.

Pages: 123456

<<<Page 5